Article Sidebar

Download
Statistic
Read Counter : 2

Main Article Content

Abstract

For thousands of years, the lungs have served as a route for drug administration. Pulmonary drug delivery is an important research area that impacts the treatment of illnesses such as asthma, chronic obstructive pulmonary disease, and other diseases. Physicians and health professionals have a wide variety of devices and formulation combinations to target specific cells or regions of the lungs, avoid the lung’s clearance mechanisms, and retain the drugs within the lung for extended periods. In recent years, several techniques have been developed to improve the quality of pulmonary drug delivery systems without affecting their stability.

Keywords

Cyclodextrins Liposomes Microemulsions Micelles Pulmonary Drug Delivery System

Article Details

License

Copyright (c) 2024 Reserved for Kabul University.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

How to Cite
Stanekzai, A. (2025). Study of Pulmonary Drug Delivery Systems. Journal of Natural Sciences – Kabul University, 4(3), 153–165. Retrieved from https://jns.edu.af/jns/article/view/243
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. Haley B, Frenkel E. Nanoparticles for drug delivery in cancer treatment. InUrologic Oncology: Seminars and original investigations 2008 Jan 1 (Vol. 26, No. 1, pp. 57-64). Elsevier.
  2. Ionescu CM. The human respiratory system. InThe human respiratory system 2013 (pp. 13-22). Springer, London.
  3. Azarmi S, Roa WH, Löbenberg R. Targeted delivery of nanoparticles for the treatment of lung diseases. Advanced drug delivery reviews. 2008 May 22; 60(8):863-75.
  4. Rahimpour Y, Hamishehkar H. Lactose engineering for better performance in dry powder inhalers. Advanced pharmaceutical bulletin. 2012 Dec; 2(2):183.
  5. Ghirardelli R, Bonasoro F, Porta C, Cremaschi D. Identification of particular epithelial areas and cells that transport polypeptide-coated nanoparticles in the nasal respiratory mucosa of the rabbit. Biochimica ET Biophysica Acta (BBA)-Biomembranes. 1999 Jan 12; 1416(1-2):39-47.
  6. Alhariri M, Azghani A, Omri A. Liposomal antibiotics for the treatment of infectious diseases. Expert opinion on drug delivery. 2013 Nov 1; 10(11):1515-32.
  7. De Leeuw J, De Vijlder HC, Bjerring P, Neumann HA. Liposomes in dermatology today. Journal of the European Academy of Dermatology and Venereology. 2009 May; 23(5):505-16.
  8. Gonzalez-Rothi RJ, Schreier H. Pulmonary delivery of liposome-encapsulated drugs in asthma therapy. Clinical Immunotherapeutics. 1995 Nov; 4(5):331-7.
  9. Malinin V, Neville M, Eagle G, Gupta R, Perkins WR. Pulmonary deposition and elimination of liposomal amikacin for inhalation and effect on macrophage function after administration in rats. Antimicrobial agents & chemotherapy. 2016 Oct 21; 60(11):6540-9.
  10. Mezzena M, Scalia S, Young PM, Traini D. Solid lipid budesonide microparticles for controlled release inhalation therapy. The AAPS journal. 2009 Dec; 11(4):771-8.
  11. Scalia S, Haghi M, Losi V, Trotta V, Young PM, Traini D. Quercetin solid lipid microparticles: a flavonoid for inhalation lung delivery. European Journal of Pharmaceutical Sciences. 2013 May 13; 49(2):278-85.
  12. Jaspart S, Piel G, Delattre L, Evrard B. Solid lipid microparticles: formulation, preparation, characterisation, drug release and applications. Expert opinion on drug delivery. 2005 Jan 1; 2(1):75-87.
  13. Mansour HM, Park CW, Hayes Jr D. Nanoparticle lung delivery and inhalation aerosols for targeted pulmonary nanomedicine. CRC Press, Taylor & Francis Group: Boca Raton, FL, USA; 2013 Jan 1.
  14. Sanna V, Kirschvink N, Gustin P, Gavini E, Roland I, Delattre L, Evrard B. Preparation and in vivo toxicity study of solid lipid microparticles as carrier for pulmonary administration. AAPS pharmscitech. 2004 Jun; 5(2):17-23.
  15. Nassimi M, Schleh C, Lauenstein HD, Hussein R, Hoymann HG, Koch W, Pohlmann GA, Krug N, Sewald K, Rittinghausen S, Braun A. A toxicological evaluation of inhaled solid lipid nanoparticles used as a potential drug delivery system for the lung. European Journal of Pharmaceutics and Biopharmaceutics. 2010 Jun 1; 75(2):107-16.
  16. Jaafar-Maalej C, Elaissari A, Fessi H. Lipid-based carriers: manufacturing & applications for pulmonary route. Expert opinion on drug delivery. 2012 Sep 1; 9(9):1111-27.
  17. Wissing SA, Kayser O, Müller RH. Solid lipid nanoparticles for parenteral drug delivery. Advanced drug delivery reviews. 2004 May 7; 56(9):1257-72.
  18. Yoon G, Park JW, Yoon IS. Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs): recent advances in drug delivery. Journal of Pharmaceutical Investigation. 2013 Oct; 43(5):353-62.
  19. Lobovkina T, Jacobson GB, Gonzalez-Gonzalez E, Hickerson RP, Leake D, Kaspar RL, Contag CH, Zare RN. In vivo sustained release of siRNA from solid lipid nanoparticles. ACS nano. 2011 Dec 27; 5(12):9977-83.
  20. Gazarian M, Henry RL, Wales SR, Micallef BE, Rood EM, O'Meara MW, Numa AH. Evaluating the effectiveness of evidence‐based guidelines for the use of spacer devices in children with acute asthma. Medical journal of Australia. 2001 Apr; 174(8):394-7.
  21. Rau JL. The inhalation of drugs: advantages and problems. Respiratory care. 2005 Mar 1; 50(3):367-82.
  22. Ungaro F, di Villa Bianca RD, Giovino C, Miro A, Sorrentino R, Quaglia F, La Rotonda MI. Insulin-loaded PLGA/cyclodextrin large porous particles with improved aerosolization properties: in vivo deposition and hypoglycaemic activity after delivery to rat lungs. Journal of controlled release. 2009 Apr 2; 135(1):25-34.